{
    "organizations": [],
    "uuid": "9275ec45397a4cffec119f1c714928638e9b8776",
    "author": "Reuters Editorial",
    "url": "https://www.reuters.com/article/brief-dar-bioscience-says-intends-to-com/brief-dar-bioscience-says-intends-to-communicate-with-u-s-fda-in-mid-2018-regarding-phase-2b-study-of-topical-sildenafil-idUSASC09UJC",
    "ord_in_thread": 0,
    "title": "BRIEF-Daré Bioscience Says Intends To Communicate With U.S. FDA In Mid-2018 Regarding Phase 2b Study Of Topical Sildenafil",
    "locations": [],
    "highlightText": "",
    "language": "english",
    "persons": [],
    "text": "April 2 (Reuters) - Dare Bioscience Inc:\n* DARÉ BIOSCIENCE, INC. REPORTS 2017 FINANCIAL RESULTS AND PROVIDES BUSINESS UPDATE\n* DARE BIOSCIENCE - INTENDS TO COMMUNICATE WITH U.S. FDA IN MID-2018 REGARDING PHASE 2B STUDY OF TOPICAL SILDENAFIL\n* ANTICIPATES COMMENCING A PHASE 2B STUDY OF TOPICAL SILDENAFIL IN Q4 OF 2018 Source text for Eikon: Further company coverage:\n ",
    "published": "2018-04-03T04:20:00.000+03:00",
    "crawled": "2018-04-03T16:07:51.001+03:00",
    "highlightTitle": "",
    "preprocessed_text": [
        "april",
        "reuters",
        "dare",
        "bioscience",
        "inc",
        "daré",
        "bioscience",
        "report",
        "financial",
        "result",
        "provides",
        "business",
        "update",
        "dare",
        "bioscience",
        "intends",
        "communicate",
        "fda",
        "regarding",
        "phase",
        "2b",
        "study",
        "topical",
        "sildenafil",
        "anticipates",
        "commencing",
        "phase",
        "2b",
        "study",
        "topical",
        "sildenafil",
        "q4",
        "source",
        "text",
        "eikon",
        "company",
        "coverage"
    ]
}